You just read:

Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes

News provided by

Eli Lilly and Company

Oct 04, 2018, 06:00 ET